Individualizing Treatment for Psoriasis: Meeting Highlights from a National Dermatology Conference
In this CME Outfitters Meeting Highlight Series, Bruce E. Strober, MD, PhD, and Joel M. Gelfand, MD, MSCE, translate insights & recommendations about current & emerging psoriasis treatment, monitoring of patients on biologics, management of comorbidities, and quality of life. You’ll get the scoop on the mechanism of action, efficacy, & safety of available and newly emerging biologics for psoriasis, as well as updates on comorbidities in patients with psoriasis.
This activity offers CE credit for:
- Physicians (CME)
All other clinicians will receive a Certificate of Attendance stating this activity was certified for AMA PRA Category 1 Credit™
Credit Expiration Date: Friday, June 30, 2017
|Bruce E. Strober, MD, PhD
Associate Professor and Interim Chair
Department of Dermatology
Director, Clinical Trials Unit
University of Connecticut School of Medicine
|Joel M. Gelfand, MD, MSCE
Professor of Dermatology
Professor of Epidemiology
Vice Chair of Clinical Research and Medical Director
Dermatology Clinical Studies Unit
Director, Psoriasis and Phototherapy Treatment Center
University of Pennsylvania Perelman School of Medicine
Psoriasis is an inflammatory, autoimmune disorder with predominately joint and skin symptoms characterized by scaling and erythematous plaques that may be painful or severely pruritic, and may cause significant quality of life issues. The systemic effects and comorbidities are not fully recognized or managed.
Psoriasis is significantly undertreated, and patients are not satisfied with their treatment. A significant number of patients with moderate-to-severe psoriasis are either untreated or treated with topical treatments alone.1
In this CME Outfitters Snack and Meeting Highlights series, expert faculty translate insights and recommendations from a national dermatology and psoriasis conference in Las Vegas, NV about current and emerging psoriasis treatment, monitoring of patients on biologics, management of comorbidities, and quality of life.
- Armstrong AW, et al. JAMA Dermatol. 2013;149(10):1180-1185.
At the end of this CE activity, participants should be able to:
- Describe the mechanism of action, efficacy, and safety of available and newly emerging biologics for psoriasis.
- Define comorbidities in patients with psoriasis.
This activity is supported by an educational grant from Lilly. For further information concerning Lilly grant funding visit www.lillygrantoffice.com.
Physicians, physician assistants, nurse practitioners, and other health care professionals with an interest in psoriasis.
CME Credit (Physicians):
CME Outfitters, LLC, is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
CME Outfitters, LLC, designates this enduring material for a maximum of .25 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Successful completion of this CE activity includes participating in the live or recorded activity, reviewing the course materials, and following the appropriate set of instructions below within 30 days of completion of the activity:
To complete your activity evaluation and post-test online, and print your certificate or statement of credit immediately (75% pass rate required), please visit www.CMEOutfitters.com/20067 (requires free account activation).
There is no fee for participation in this activity. The estimated time for completion is 15 minutes.
It is the policy of CME Outfitters, LLC, to ensure independence, balance, objectivity, and scientific rigor and integrity in all of their CME/CE activities. Faculty must disclose to the participants any relationships with commercial companies whose products or devices may be mentioned in faculty presentations, or with the commercial supporter of this CME/CE activity. CME Outfitters, LLC, has evaluated, identified, and attempted to resolve any potential conflicts of interest through a rigorous content validation procedure, use of evidence-based data/research, and a multidisciplinary peer review process. The following information is for participant information only. It is not assumed that these relationships will have a negative impact on the presentations.
Dr. Strober has disclosed that he has received research and grant support from AbbVie Inc. and Janssen Pharmaceuticals, Inc. He serves as a consultant for AbbVie Inc.; Amgen Inc.; Boehringer Ingelheim; Celgene Corporation; Dermira; Forward Pharma A/S; Janssen Pharmaceuticals, Inc.; Eli Lilly and Company; Maruho Co., Ltd.; Medac Pharma, Inc.; Novartis; Pfizer Inc.; and UCB, Inc. He is on the speaker’s bureau for AbbVie Inc. He serves as an investigator for AbbVie Inc.; Amgen Inc.; Celgene Corporation; Novartis; Eli Lilly and Company; Janssen Pharmaceuticals, Inc.; Merck & Co., Inc.; XenoPort, Inc.; and XOMA. He is a scientific director for CORRONA Psoriasis Registry.
Dr. Gelfand has disclosed that he has received research and grant support (to the Trustees of the University of Pennsylvania) from AbbVie Inc.; Amgen Inc.; Eli Lilly and Company; and Janssen Biologics, Inc.; Novartis Pharmaceuticals Corporation; Regeneron Pharmaceuticals, Inc.; and Pfizer Inc. He serves as a consultant for AbbVie Inc.; AstraZeneca; Celgene Corporation; Coherus Biosciences; Eli Lilly and Company; Endo Pharmaceuticals Inc.; Janssen Biologics, Inc. (formerly Centocor Biotech, Inc.; Leo Pharma, Inc.; Merck & Co., Inc.; Novartis Pharmaceuticals Corporation; Pfizer Inc.; and sanofi-aventis U.S., LLC.
Erica Perilstein, MD (peer reviewer) has nothing to disclose.
Frances Daniel, MPH (planning committee) has nothing to disclose.
Sharon Tordoff, CCMEP (planning committee) has nothing to disclose.
Disclosures were obtained from the CME Outfitters, LLC staff: Nothing to disclose.
CME Outfitters, LLC, the faculty, and Lilly do not endorse the use of any product outside of the FDA labeled indications. Medical professionals should not utilize the procedures, products, or diagnosis techniques discussed during this activity without evaluation of their patient for contraindications or dangers of use.